Payers

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

FDA Told a Promising ADC: Not Yet.

Cholangiocarcinoma Just Made FGFR2 Testing Harder to Ignore

Breast Cancer Radiation De-Escalation Has an Adherence Problem

Pembrolizumab Just Lost a Head-to-Head Survival Fight

SMA Treatment Finally Reaches the Muscle

HER2-Mutant Lung Cancer Just Moved Into First Line

One Psychedelic Dose Is Now a Phase III Argument
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
